Teva launches Olanzapine and Fluoxetine Capsules for treatment of depression

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the launch of Olanzapine and Fluoxetine Capsules USP 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, and 12 mg/50 mg, the Company's generic equivalent of Symbyax®.

Symbyax® is marketed by Lilly USA and approved for the acute treatment of treatment-resistant depression and bipolar I depression in adults. The brand product had annual sales of approximately $82 million in the United States, based on IMS sales data.

Source: Teva Pharmaceutical Industries Ltd.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Study identifies link between oral and gut microbiomes and depression